4.1 Summary View Company | Role | GLP-1 / Tirzepatide Link | Investment Angle --------------------------------|--------------------------|----------------------------------------------------|----------------- Divi's Labs | CDMO - peptides / APIs | Likely supplier of GLP-1 fragments and oral inputs | Primary Cipla | Commercial partner (IN) | Distributor / marketer of Yurpeak (tirzepatide) | High-quality Syngene | CRDMO / biologics | Biologics, analytics and development support | Secondary Piramal Pharma | CDMO / injectables | Fill-finish and sterile injectable capacity | Secondary Biocon Biologics, Gland, Laurus | Biologics & formulations | Biologics, injectables, GLP-1-related outsourcing | Thematic 4.2 Divis Laboratories: The Purest GLP1 Manufacturing Play Divis Laboratories stands out for one reason: peptide and complex intermediate chemistry
Diabetes Metab (2008) 34:6572
I know these are little acts
Finally, similar to GLP-1 RAs, the medication should not be used in patients with a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [31, 43]
That said, Ozempic has a longer track record and broader availability, which matters for people who value proven, established treatments
This case raised questions about whether GLP-1 medications might trigger autoimmune responses in susceptible individuals, adding another layer of complexity to an already nuanced picture
